Glenmark Pharmaceuticals Q3 results 2025 on 15 Feb, 2025: profit at ₹347.96Cr, Revenue increased by 35.14% YoY
Glenmark Pharmaceuticals Q3 results 2025 on 15 Feb, 2025: Revenue increased by 35.14% YoY & profit at ₹347.96Cr
Glenmark Pharmaceuticals Q3 Results 2025:Glenmark Pharmaceuticals declared their Q3 results on 14 Feb, 2025, revealing a significant increase in topline by 35.14%, with profit reaching ₹347.96 Cr. This marks a remarkable turnaround from the loss of ₹351.37 Cr reported during the same period in the previous fiscal year.
Despite the impressive year-over-year growth, the company experienced a slight decline of 1.35% in revenue compared to the previous quarter. Additionally, the Selling, General & Administrative expenses rose by 0.25% quarter-on-quarter and increased by 4.71% year-on-year.
Glenmark Pharmaceuticals Q3 Results
The operating income saw a decrease of 0.86% compared to the previous quarter but displayed a substantial increase of 210.42% year-on-year. The Earnings Per Share (EPS) stood at ₹12.33 for Q3, reflecting a remarkable increase of 182.81% compared to the same quarter last year.
Glenmark Pharmaceuticals has faced challenges in the stock market, delivering -14.1% return over the last week, -15.5% return in the past six months, and -17.78% return year-to-date.
Currently, Glenmark Pharmaceuticals boasts a market capitalization of ₹37318.59 Cr, with a 52-week high of ₹1830.95 and a low of ₹822.
As of 15 Feb, 2025, out of 10 analysts covering the company, 1 has issued a Sell rating, 4 have given a Hold rating, 1 has recommended a Buy rating, and 4 have given a Strong Buy rating. The consensus recommendation on this date was to Buy.
Glenmark Pharmaceuticals Financials
| Period | Q3 (FY25) | Q2 (FY25) | Q-o-Q Growth | Q3 (FY24) | Y-o-Y Growth |
|---|---|---|---|---|---|
| Total Revenue | 3387.55 | 3433.8 | -1.35% | 2506.7 | +35.14% |
| Selling/ General/ Admin Expenses Total | 788.49 | 786.56 | +0.25% | 753.04 | +4.71% |
| Depreciation/ Amortization | 122.74 | 120.28 | +2.05% | 147.08 | -16.55% |
| Total Operating Expense | 2910.06 | 2952.16 | -1.43% | 2939.15 | -0.99% |
| Operating Income | 477.49 | 481.63 | -0.86% | -432.45 | +210.42% |
| Net Income Before Taxes | 456.33 | 472.57 | -3.44% | -521.38 | +187.52% |
| Net Income | 347.96 | 354.21 | -1.76% | -351.37 | +199.03% |
| Diluted Normalized EPS | 12.33 | 12.55 | -1.75% | -14.89 | +182.81% |
Disclaimer: This is an AI-generated live blog and has not been edited by LiveMint staff.
Catch all the Business News , Corporate news , Breaking News Events and Latest News Updates on Live Mint. Download The Mint News App to get Daily Market Updates.
- Top Gainers
- Top Losers
- 52 Week High